Form 4: Integra LifeSciences CEO Jan De Witte Reports Stock Transactions
SEC Form 4 Filing
CEO Jan De Witte reports acquisition and disposal of Integra LifeSciences Holdings Corp stock and derivative securities on March 11, 2024.
Summary
- On March 11, 2024, Jan De Witte, President & CEO of Integra LifeSciences Holdings Corp, reported transactions involving the company's stock.
- These transactions included the acquisition of 205 shares of Common Stock at $0 and the disposal of 205 shares at $36.22.
- Following these transactions, De Witte directly owns 18,350 shares of Common Stock.
- De Witte also acquired 95,664 Non-Qualified Stock Options exercisable at $36.22, vesting in installments from March 11, 2024, and expiring on March 11, 2032.
- Additionally, De Witte acquired 41,414 Restricted Stock Units (RSUs) vesting in equal annual installments from March 11, 2024.
- He also holds 130,280 Restricted Stock Units after a transaction involving 205 units.
- The RSUs are subject to deferred delivery and accelerated vesting under certain conditions, such as termination due to death or disability, or a qualifying termination following a change in control.
Sentiment
Score: 5
Explanation: This is a routine regulatory filing, so the sentiment is neutral. It simply reports transactions.
Future Outlook
The reported transactions reflect ongoing compensation and equity ownership adjustments for the CEO, with vesting schedules extending into the future.
Industry Context
Form 4 filings are standard disclosures required by the SEC to provide transparency into the transactions of company insiders, allowing investors to monitor executive compensation and potential alignment of interests.
Comparison to Industry Standards
- Executive compensation packages often include stock options and restricted stock units to align management's interests with those of shareholders.
- Vesting schedules for stock options and RSUs are common, typically ranging from three to five years.
- The specific terms of these awards, such as vesting schedules and performance conditions, are often benchmarked against peer companies in the life sciences industry to ensure competitiveness.
Stakeholder Impact
- The filing provides transparency to shareholders regarding executive compensation and stock ownership.
- The transactions themselves have a minimal direct impact on other stakeholders.
Key Dates
| Date | Description |
|---|---|
| 03/11/2022 | Grant date of a restricted stock unit award, with installments vesting annually. |
| 03/11/2024 | Date of reported transactions: stock acquisition/disposal, stock option grant, and RSU grant. |
| 03/13/2024 | Date of signature by Attorney-in-Fact. |
| 03/11/2032 | Expiration date of the Non-Qualified Stock Options. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.